***Background.*** Previous antimicrobial resistance (AR) reports from the National Healthcare Safety Network (NHSN) have aggregated data across intensive care unit (ICU) types. Pediatric specific data are needed to guide prevention. We describe central line-associated bloodstream infection (CLABSI) pathogens and AR in pediatric and neonatal ICUs (PICUs and NICUs).

***Methods.*** Among pathogens implicated in CLABSIs and reported with antimicrobial susceptibility test results to NHSN for the years 2011-2013, proportions testing resistant (R) or nonsusceptible (NS) to ampicillin (AMP-R), methicillin (MR), carbapenems (imipenem, meropenem or doripenem, CARB-NS), extended-spectrum cephalosporins (ESC-NS), and fluconazole (FLC-R) were determined. Log binomial regression was used to detect differences in %R/NS between ICU types.

***Results.*** 2472 CLABSI due to 2797 organisms were reported from 320 PICUs, and 5720 CLABSI due to 6121 organisms were reported from 734 NICUs. Pathogen distribution differed in the 2 unit types (Table); staphylococci caused 54% of NICU CLABSI as compared to 29% of PICU CLABSI. Although proportions of resistant *S. aureus*, *Enterococcus* and *Candida* spp. were similar in the 2 ICU types, ESC-NS among Enterobacteriaceae causing CLABSI was significantly more common in the PICU than the NICU.

  Pathogen                            PICU CLABSI Pathogens   NICU CLABSI Pathogens   P-value                 
  ----------------------------------- ----------------------- ----------------------- --------- ------------- ---------
  Coagulase-negative staphylococci    1                       457 (16.3)              1         1835 (30.0)   \<.0001
  *Enterococcus* *faecalis*           2                       361 (12.9)              3         501 (8.2)     \<.0001
   %AMP-R                                                     1.6                               2.2           0.53
  *Staphylococcus* *aureus*,          3                       360 (12.9)              2         1460 (23.9)   \<.0001
  * *%MR                                                      31.8                              32.1          0.92
  *Klebsiella* *pneumoniae/oxytoca*   4                       288 (10.3)              5         415 (6.8)     \<.0001
  * *%ESC-NS                                                  14.6                              4.5           \<.0001
  * *%CARB-NS                                                 1.4                               0.3           0.22
  *Enterobacter* spp.                 5                       213 (7.6)               7         244 (4.0)     \<.0001
   %ESC-NS                                                    44.8                              27.0          .002
   %CARB-NS                                                   4.0                               3.2           0.67
  *Candida* spp., non-*albicans*      6                       199 (7.1)               6         249 (4.1)     \<.0001
   %FLC-R                                                     4.3                               6.3           0.57
  *Candida* *albicans*                7                       125 (4.5)               8         208 (3.4)     0.01
   %FLC-R                                                     1.5                               3.9           0.42
  *Pseudomonas* *aeruginosa*          8                       104 (3.7)               9         161 (2.6)     0.01
  * *%CARB-NS                                                 17.2                              7.6           0.03
  *Escherichia coli*                  9                       91 (3.3)                4         471 (7.7)     \<.0001
   %ESC-NS                                                    17.9                              10.3          0.05
   %CARB-NS                                                   1.4                               2.1           0.72

***Conclusion.*** Pathogen profiles and AR patterns in PICUs and NICUs are distinct. To better inform interventions to reduce AR spread in hospitals, data from neonatal, pediatric and adult locations should be reported separately.
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